Reactive Oxygen Species in trEatment-resistant hypertension treated with denervation of the sympathetic nerves

Withdrawn

• Conditions: high blood pressure; oxidative stress; 10057166

• Registration Number: NL-OMON38954
• Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 30

Inclusion Criteria

1. Individual is accepted for treatment with renal denervation as standard therapy for resistant hypertension.
2. Individual is *18 years of age.
3.Individual agrees to have all study procedures performed, and is competent and willing to provide written
informed consent to participate in this clinical study.

Exclusion Criteria

1. Individual is excluded from treatment with pRDN.
2. Individual has an estimated glomerular filtration rate (eGFR) of <30mL/min/1.73m2, using the MDRD calculation.
3. Individual is pregnant, nursing or planning to be pregnant.
4. Individual has a known, unresolved history of drug use or alcohol dependency, lacks the ability to comprehend or follow instructions, or would be unlikely or unable to comply with study follow-up requirements.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The effect of renal denervation on markers of oxidative stress present in<br /><br>blood, urine and isolated leukocytes. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>To determine whether blood pressure, insulin resistance, kidney function and<br /><br>lipid profile are related to ROS production. </p><br>